Litcius/Paper detail

Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis

Thiago de Amorim Carvalho

2023Nature Medicine9 citationsDOI

Topics & Concepts

Multiple sclerosisMedicineTranslational researchDiseaseTranslational medicineAntibodyClinical researchImmunologyClinical efficacyAutoimmune diseaseIntensive care medicineInternal medicinePathologyMonoclonal and Polyclonal Antibodies Research
Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis | Litcius